4.3 Article

Magnetic Resonance Image Guided Brachytherapy

期刊

SEMINARS IN RADIATION ONCOLOGY
卷 24, 期 3, 页码 181-191

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semradonc.2014.02.007

关键词

-

资金

  1. Varian Medical Systems, Nucletron-an Elekta Company
  2. Varian Medical Systems
  3. Nucletron
  4. Austrian Science Fund (FWF) [L 562] Funding Source: researchfish

向作者/读者索取更多资源

The application of magnetic resonance image (MRI)-guided brachytherapy has demonstrated significant growth during the past 2 decades. Clinical improvements in cervix cancer outcomes have been linked to the application of repeated MRI for identification of residual tumor volumes during radiotherapy. This has changed clinical practice in the direction of individualized dose administration, and resulted in mounting evidence of improved clinical outcome regarding local control, overall survival as well as morbidity. MRI-guided prostate high-dose-rate and low-dose-rate brachytherapies have improved the accuracy of target and organs-at-risk delineation, and the potential exists for improved dose prescription and reporting for the prostate gland and organs at risk. Furthermore, MRI-guided prostate brachytherapy has significant potential to identify prostate subvolumes and dominant lesions to allow for dose administration reflecting the differential risk of recurrence. MRI-guided brachytherapy involves advanced imaging, target concepts, and dose planning. The key issue for safe dissemination and implementation of high-quality MRI-guided brachytherapy is establishment of qualified multidisciplinary teams and strategies for training and education. (C) 2014 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据